Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future Prospects.

Abstract

Ra-223 (radium-223) is an alpha particle-emitting radiopharmaceutical with targeted uptake in areas of osteoblastic lesions. The combination of targeted skeletal uptake, short tissue-penetration range, and high energy of alpha particles allows for targeted cell killing and a low toxicity profile. A phase III trial (ALSYMPCA) demonstrated improvements in overall survival and symptomatic skeletal events in patients with castration-resistant prostate cancer and multifocal symptomatic bone metastases. Adverse events were limited but included both gastrointestinal and hematologic effects. This article will describe the historic background of Ra-223; outline the clinical studies which led to phase III trials of this agent; highlight key results of these phase III studies; and explore possible future directions for use of Ra-223 and other alpha particles--both in prostate cancer and for management of other diseases.

• Authors: Brian Lewis, Elie Chalhoub, Carla Chalouhy, Oliver Sartor
• Journal: Oncology (Williston Park, N.Y.) (Oncology (Williston Park)) Vol. 29 Issue 7 Pg. 483-8 (Jul 2015) ISSN: 0890-9091 [Print] United States
• PMID: 26178336 (Publication Type: Journal Article, Review)

Chemical References

• Alkaline Phosphatase
• Radium

Topics

• Alkaline Phosphatase (blood)
• Bone Neoplasms (radiotherapy, secondary)
• Clinical Trials as Topic
• Humans
• Male
• Prostatic Neoplasms (mortality, pathology, radiotherapy)
• Radium (therapeutic use)